Oncology

关注
Illustration depicting a self-reinforcing SRSF1–AURKA–MYC molecular circuit in pancreatic cancer cells, disrupted by an antisense oligonucleotide therapy.
AI 生成的图像

Study maps self-reinforcing SRSF1–AURKA–MYC circuit in pancreatic cancer cells

由 AI 报道 AI 生成的图像 事实核查

Researchers at Cold Spring Harbor Laboratory report they have identified a three-part molecular circuit involving SRSF1, Aurora kinase A (AURKA) and MYC that helps drive aggressive pancreatic ductal adenocarcinoma. In laboratory models, a splice-switching antisense oligonucleotide designed to alter AURKA splicing disrupted the circuit, reducing tumor-cell viability and triggering programmed cell death.

An alliance between Clínica Medilaser and the Instituto Médico Oncológico has consolidated an integrated program to treat central nervous system tumors in southern Colombia. The service, led by neurosurgeon Silvia Quintero, serves patients from several regions from its Neiva site.

由 AI 报道

One month after the nationwide oncology sanitary alert took effect, Health Minister May Chomali led the signing of a decree transferring $154 billion from the Ministry of Hacienda to the Ministry of Health (Minsal). The funds will exclusively support the Oncology Alert Plan, enhancing public health services' capacity to resolve oncology waiting lists affecting thousands of patients.

Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.

由 AI 报道

Oncologist Paulo Hoff warned that excessive sun exposure is the most common cause of cancer, particularly non-melanoma skin cancer. In a course on CasaFolha, he emphasizes the importance of prevention and early diagnosis to boost cure rates. Hoff recommends avoiding the sun between 10am and 2pm and using sunscreen.

A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.

由 AI 报道

Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝